-
Pharma Mafia Wants To Conquer Cannabis: Can You Patent A Plant? Jazz Is Trying
Tuesday, March 7, 2023 - 12:05pm | 1264The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) recently published collected data on CBD safety, placing the information under its Yellow Card alert system, which lists various adverse reactions to drugs in general. In the report, the agency notes that as many as 10 people...
-
CBD-Based Life-Changing Drug For Tuberous Sclerosis Patients, Epidiolex, Now Available Via England's NHS
Thursday, February 2, 2023 - 9:50am | 1101The National Health Service England confirmed Tuesday that starting this week, doctors can prescribe Jazz Pharmaceuticals (NASDAQ: JAZZ) Epidiolex, a CBD-based medicine, to patients suffering from tuberous sclerosis complex (TSC). This means that patients who use...
-
Jazz Pharmaceuticals Files Patent Infringement Against Generic Drugmakers In New Jersey's District Court
Thursday, January 5, 2023 - 6:45pm | 554Jazz Pharmaceuticals (NASDAQ: JAZZ), a drug company behind the CBD-based medication Epidiolex, recently filed a lawsuit against Teva Pharmaceutical Industries Ltd (NYSE: TEVA), Apotex, Alkem and several other generic drugmakers alleging patent infringement on the cannabis-derived therapy...
-
Police Raids Dying Man's Hospital Room For Marijuana Extracts, Overreact Much?
Tuesday, December 27, 2022 - 2:07pm | 573Cannabis in Kansas is entirely illegal and penalties for possession are steep. A 69-year-old patient at Hays Medical Center who is in the final stages of terminal, inoperable cancer might face arrest for possessing a vaping device and edible THC paste earlier this month. That is if...
-
Jazz Pharmaceuticals Announces Q3 2022 Financial Results, Raises Total Revenue Guidance
Thursday, November 10, 2022 - 10:07am | 569Jazz Pharmaceuticals plc (NASDAQ: JAZZ) announced its financial results late Wednesday for the third quarter of 2022 and raised the mid-point of 2022 total revenue guidance. "Our execution across our business continues to chart a clear path to delivering on Vision 2025. We have...
-
Cannabis Drugs Market Could Exceed $2013.42B By 2030, Says New Report
Friday, October 7, 2022 - 8:54am | 645According to new market research published by Growth+Reports, a part of GRG Health, a global healthcare knowledge service company, the cannabis drugs market is expected to grow at a CAGR of 59% from 2021 to reach US$ 2013.42 billion by 2030. This is "owing to regulatory relaxation and...
-
Japan Is Inching Toward Cannabis Legalization, Companies Like This One Could Benefit
Thursday, September 29, 2022 - 2:28pm | 497A Japanese health ministry panel recommended that marijuana-derived medicines be treated the same as pharmaceuticals, reported Bloomberg. The expert panel, convened on Thursday, recommended a revision of the country's policy on drugs to enable the import, manufacture and use of...
-
North Carolina House Says Yes To Bill Allowing FDA-Approved THC Drugs, Will This Kill Full Medical Marijuana Legalization?
Thursday, June 9, 2022 - 10:46am | 624The North Carolina House passed Senate Bill 448, legalizing FDA-approved THC medications in a 92-9 vote, reported The Carolina Journal. The move came on the heels of the Senate’s approval of a medical marijuana bill known as N.C. Compassionate Care Act, which would...
-
Kansas Patients Now Have Access To Medicinal Cannabis Without A State Law
Friday, June 3, 2022 - 5:33pm | 448On June 2, Governor Laura Kelly (D) signed new legislation that would allow Kansans to obtain prescription drugs derived from cannabis-related products. Although medical marijuana is not yet legalized in the state, the bill will allow residents to obtain cannabis-derived medications, as long as...
-
FDA Battles Over CBD Hype Yet Again, This Time Warns Businesses Selling Illegal CBD For Food-Producing Animals
Friday, May 27, 2022 - 8:33am | 643The Food and Drug Administration (FDA) sent letters to four CBD companies warning them against selling unauthorized CBD products for use in food-producing animals. Companies being warned are Haniel Concepts (doing business as Free State Oils), Hope Botanicals, Plantacea LLC (doing...
-
Jazz Pharma Getting New State-Of-The-Art Facility For Cannabis-Based Research And Production
Friday, March 25, 2022 - 9:00am | 420Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and its subsidiary, GW Pharmaceuticals have begun construction of its new, state-of-the-art manufacturing facility at Kent Science Park (KSP) in Sittingbourne, UK, with an investment of over $100 million. The new facility, expected to be...
-
Court Dismisses Canopy's Cannabis Patent Infringement Lawsuit Against Jazz's GW Pharma
Thursday, March 3, 2022 - 9:30am | 777The U.S. District Court for the Western District of Texas dismissed a lawsuit filed by Canadian cannabis giant Canopy Growth (NASDAQ: CGC) against GW Pharmaceuticals on Feb. 25th. The lawsuit was initially filed in 2020, and since then, Britain’s GW Pharma was...
-
Jazz Pharmaceuticals Announces Full Year And 4Q 2021 Financial Results
Tuesday, March 1, 2022 - 7:12pm | 709Jazz Pharmaceuticals plc (NASDAQ: JAZZ), a global biopharmaceutical company and manufacturer of Epidolex, announced its financial results late Tuesday for the full year and fourth quarter of 2021 and provided financial guidance for 2022. "2021 was a transformative year for Jazz,...
-
Jazz Pharmaceuticals Q2 Revenue Jumps 34% To $751.8M With $109.5M Epidiolex Net Sales, Reaffirms Its 2021 Guidance Of $3.02B
Wednesday, August 4, 2021 - 10:29am | 657Biopharmaceutical company Jazz Pharmaceuticals plc (NASDAQ: JAZZ) reported its financial results on Tuesday for the second quarter of 2021 with total revenue of $751.81 million, up by 34% from $562.43 million in the comparative period of 2020. Financial...
-
Does Big Business Provide A Better Look Into Cannabis Reform Than Capitol Hill? Operators Believe So.
Thursday, July 29, 2021 - 9:20am | 874Cannabis operators and executives tell Benzinga that the movement of private and public companies may serve as a better indicator of regulatory activity than the federal government. At the very least, they say that the industry has made advancements so far without the efforts of Capitol Hill....